Hendrik Andreas Wolff
Research Subjects
Hendrik Andreas Wolff has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Steffen Hennies
Dept. of Radiotherapy and Radiooncology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Germany
4 shared publications- Clemens Friedrich Hess
Klinik und Poliklinik für Strahlentherapie und Radioonkologie der Georg-August-Universität Göttingen
3 shared publications Hans Christiansen
3 shared publicationsC.F. Hess
2 shared publicationsClemens F. Hess
Departments of Radiotherapy and Radiooncology, University Medical Center Göttingen, Göttingen, Germany
2 shared publicationsH. Christiansen
Universitätsmedizin Göttingen
2 shared publications
Latest Publications
- Open Access
- 15 April 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (4) , 568
Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer
Background: Patients with locally advanced rectal cancer are treated with preoperative chemoradiotherapy followed by surgical resection. Despite similar clinical parameters (uT2-3, uN+) and standard therapy, patients’ prognoses differ widely. A possible prediction of prognosis through microRNAs as biomarkers out of treatment-naïve biopsies would allow individualized therapy options. Methods: Microarray analysis of 45 microdissected preoperative biopsies from patients with rectal cancer was performed to identify potential microRNAs to predict overall survival, disease-free survival, cancer-specific survival, distant-metastasis-free survival, tumor regression grade, or nodal stage. Quantitative real-time polymerase chain reaction (qPCR) was performed on an independent set of 147 rectal cancer patients to validate relevant miRNAs. Results: In the microarray screen, 14 microRNAs were significantly correlated to overall survival. Five microRNAs were included from previous work. Finally, 19 miRNAs were evaluated by qPCR. miR-515-5p, miR-573, miR-579 and miR-802 demonstrated significant correlation with overall survival and cancer-specific survival (p < 0.05). miR-573 was also significantly correlated with the tumor regression grade after preoperative chemoradiotherapy. miR-133b showed a significant correlation with distant-metastasis-free survival. miR-146b expression levels showed a significant correlation with nodal stage. Conclusion: Specific microRNAs can be used as biomarkers to predict prognosis of patients with rectal cancer and possibly stratify patients’ therapy if validated in a prospective study.
- 15 April 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (4) , 568
Open AccessPrognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer
Background: Patients with locally advanced rectal cancer are treated with preoperative chemoradiotherapy followed by surgical resection. Despite similar clinical parameters (uT2-3, uN+) and standard therapy, patients’ prognoses differ widely. A possible prediction of prognosis through microRNAs as biomarkers out of treatment-naïve biopsies would allow individualized therapy options. Methods: Microarray analysis of 45 microdissected preoperative biopsies from patients with rectal cancer was performed to identify potential microRNAs to predict overall survival, disease-free survival, cancer-specific survival, distant-metastasis-free survival, tumor regression grade, or nodal stage. Quantitative real-time polymerase chain reaction (qPCR) was performed on an independent set of 147 rectal cancer patients to validate relevant miRNAs. Results: In the microarray screen, 14 microRNAs were significantly correlated to overall survival. Five microRNAs were included from previous work. Finally, 19 miRNAs were evaluated by qPCR. miR-515-5p, miR-573, miR-579 and miR-802 demonstrated significant correlation with overall survival and cancer-specific survival (p < 0.05). miR-573 was also significantly correlated with the tumor regression grade after preoperative chemoradiotherapy. miR-133b showed a significant correlation with distant-metastasis-free survival. miR-146b expression levels showed a significant correlation with nodal stage. Conclusion: Specific microRNAs can be used as biomarkers to predict prognosis of patients with rectal cancer and possibly stratify patients’ therapy if validated in a prospective study.
- 1 October 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (2) , 313-315
The EXPERT-C Trial Defines a Reference for Future Research: Quality of Life and Bowel Function in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemotherapy Followed by Chemoradiation Therapy Before Surgery
- 1 October 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (2) , 313-315
The EXPERT-C Trial Defines a Reference for Future Research: Quality of Life and Bowel Function in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemotherapy Followed by Chemoradiation Therapy Before Surgery
- 15 September 2015
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 192 (1) , 47-54
Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma
The chemokine CXCL12 and its receptor CXCR4 can affect tumor growth, recurrence, and metastasis. We tested the hypothesis that the CXCL12 and CXCR4 expression influences the prognosis of patients with inoperable head and neck cancer treated with definite radiotherapy or chemoradiotherapy. Formalin-fixed paraffin-embedded pretreatment tumor tissue from 233 patients with known HPV/p16INK4A status was analyzed. CXCL12 and CXCR4 expressions were correlated with pretreatment parameters and survival data by univariate and multivariate Cox regression. CXCL12 was expressed in 43.3 % and CXCR4 in 66.1 % of the samples and both were correlated with HPV/p16INK4A positivity. A high CXCL12 expression was associated with increased overall survival (p = 0.036), while a high CXCR4 expression was associated with decreased metastasis-free survival (p = 0.034). A high CXCR4 expression could be regarded as a negative prognostic factor in head and neck cancer because it may foster metastatic spread. This may recommend CXCR4 as therapeutic target for combating head and neck cancer metastasis.
- 15 September 2015
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 192 (1) , 47-54
Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma
The chemokine CXCL12 and its receptor CXCR4 can affect tumor growth, recurrence, and metastasis. We tested the hypothesis that the CXCL12 and CXCR4 expression influences the prognosis of patients with inoperable head and neck cancer treated with definite radiotherapy or chemoradiotherapy. Formalin-fixed paraffin-embedded pretreatment tumor tissue from 233 patients with known HPV/p16INK4A status was analyzed. CXCL12 and CXCR4 expressions were correlated with pretreatment parameters and survival data by univariate and multivariate Cox regression. CXCL12 was expressed in 43.3 % and CXCR4 in 66.1 % of the samples and both were correlated with HPV/p16INK4A positivity. A high CXCL12 expression was associated with increased overall survival (p = 0.036), while a high CXCR4 expression was associated with decreased metastasis-free survival (p = 0.034). A high CXCR4 expression could be regarded as a negative prognostic factor in head and neck cancer because it may foster metastatic spread. This may recommend CXCR4 as therapeutic target for combating head and neck cancer metastasis.
- 8 June 2015
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 191 (11) , 827-834
Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma
Primary chemoradiotherapy (CRT) is the standard treatment for locally advanced anal carcinoma. This study compared volumetric intensity-modulated arc therapy (VMAT) to 3-dimensional conformal radiotherapy (3DCRT) in terms of treatment-related side effects and survival. From 1992–2014, 103 consecutive patients with anal carcinoma UICC stage I–III were treated. Concomitant CRT consisted of whole pelvic irradiation, including the iliac and inguinal lymph nodes, with 50.4 Gy (1.8 Gy per fractions) by VMAT (n = 17) or 3DCRT (n = 86) as well as two cycles of 5-fluorouracil and mitomycin C. Acute organ and hematological toxicity were assessed according to the Common Terminology Criteria (CTC) for Adverse Events version 3.0. Side effects ≥ grade 3 were scored as high-grade toxicity. High-grade acute organ toxicity CTC ≥ 3 (P < 0.05), especially proctitis (P = 0.03), was significantly reduced in VMAT patients. The 2-year locoregional control (LRC) and disease-free survival (DFS) were both 100 % for VMAT patients compared with 80 and 73 % for 3DCRT patients. VMAT was shown to be a feasible technique, achieving significantly lower rates of acute organ toxicity and promising results for LRC and DFS. Future investigations will aim at assessing the advantages of VMAT with respect to late toxicity and survival after a prolonged follow-up time. Die primäre Radiochemotherapie (RCT) gilt als Standardtherapie für lokal fortgeschrittene Analkarzinome. In dieser Studie wurde die volumetrisch modulierte Rotationstherapie („volumetric intensity-modulated arc therapy“, VMAT) mit der klassischen dreidimensionalen konformalen Radiotherapie (3DCRT) hinsichtlich therapieassoziierter Nebenwirkungen und Überleben verglichen. Von 1992–2014 wurden 103 aufeinanderfolgende Patienten mit einem Analkarzinom im UICC-Stadium I–III behandelt. Die kombinierte RCT bestand aus der Bestrahlung des gesamten Beckens inklusive der iliakalen und der inguinalen Lymphknoten mit einer Gesamtdosis von 50,4 Gy (1,8 Gy pro Fraktion) entweder mit VMAT (n = 17) oder 3DCRT (n = 86) sowie zwei begleitenden Chemotherapiezyklen mit 5-Fluorouracil und Mitomycin C. Alle akuten Organ- und/oder hämatologischen Nebenwirkungen wurden gemäß der Common Terminology Criteria (CTC) for Adverse Events Version 3.0 erfasst. Nebenwirkungen ≥ Grad 3 wurden als hochgradige Toxizität gewertet. Die VMAT-Patienten entwickelten insgesamt signifikant weniger hochgradige (CTC ≥ 3) Akutnebenwirkungen an den Organen bzw. im gesunden Gewebe (P < 0,05), insbesondere die Proktitis (P = 0,03) war verringert. Die lokoregionäre Tumorkontrolle (LRC) und das erkrankungsfreie Überleben (DFS) lagen nach 2 Jahren bei 100 % für alle VMAT-Patienten verglichen mit 80 und 73 % für die 3DCRT-Patienten. VMAT hat sich als eine praktikable Radiotherapietechnik bewiesen, die signifikant niedrigere Raten an akuter Organtoxizität und vielversprechende LRC- und DFS-Ergebnisse zeigt. Zukünftige Untersuchungen sollten darauf abzielen, die Vorteile von VMAT in Hinblick auf die Spättoxizität und das Langzeitüberleben zu analysieren.
- 8 June 2015
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 191 (11) , 827-834
Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma
Primary chemoradiotherapy (CRT) is the standard treatment for locally advanced anal carcinoma. This study compared volumetric intensity-modulated arc therapy (VMAT) to 3-dimensional conformal radiotherapy (3DCRT) in terms of treatment-related side effects and survival. From 1992–2014, 103 consecutive patients with anal carcinoma UICC stage I–III were treated. Concomitant CRT consisted of whole pelvic irradiation, including the iliac and inguinal lymph nodes, with 50.4 Gy (1.8 Gy per fractions) by VMAT (n = 17) or 3DCRT (n = 86) as well as two cycles of 5-fluorouracil and mitomycin C. Acute organ and hematological toxicity were assessed according to the Common Terminology Criteria (CTC) for Adverse Events version 3.0. Side effects ≥ grade 3 were scored as high-grade toxicity. High-grade acute organ toxicity CTC ≥ 3 (P < 0.05), especially proctitis (P = 0.03), was significantly reduced in VMAT patients. The 2-year locoregional control (LRC) and disease-free survival (DFS) were both 100 % for VMAT patients compared with 80 and 73 % for 3DCRT patients. VMAT was shown to be a feasible technique, achieving significantly lower rates of acute organ toxicity and promising results for LRC and DFS. Future investigations will aim at assessing the advantages of VMAT with respect to late toxicity and survival after a prolonged follow-up time. Die primäre Radiochemotherapie (RCT) gilt als Standardtherapie für lokal fortgeschrittene Analkarzinome. In dieser Studie wurde die volumetrisch modulierte Rotationstherapie („volumetric intensity-modulated arc therapy“, VMAT) mit der klassischen dreidimensionalen konformalen Radiotherapie (3DCRT) hinsichtlich therapieassoziierter Nebenwirkungen und Überleben verglichen. Von 1992–2014 wurden 103 aufeinanderfolgende Patienten mit einem Analkarzinom im UICC-Stadium I–III behandelt. Die kombinierte RCT bestand aus der Bestrahlung des gesamten Beckens inklusive der iliakalen und der inguinalen Lymphknoten mit einer Gesamtdosis von 50,4 Gy (1,8 Gy pro Fraktion) entweder mit VMAT (n = 17) oder 3DCRT (n = 86) sowie zwei begleitenden Chemotherapiezyklen mit 5-Fluorouracil und Mitomycin C. Alle akuten Organ- und/oder hämatologischen Nebenwirkungen wurden gemäß der Common Terminology Criteria (CTC) for Adverse Events Version 3.0 erfasst. Nebenwirkungen ≥ Grad 3 wurden als hochgradige Toxizität gewertet. Die VMAT-Patienten entwickelten insgesamt signifikant weniger hochgradige (CTC ≥ 3) Akutnebenwirkungen an den Organen bzw. im gesunden Gewebe (P < 0,05), insbesondere die Proktitis (P = 0,03) war verringert. Die lokoregionäre Tumorkontrolle (LRC) und das erkrankungsfreie Überleben (DFS) lagen nach 2 Jahren bei 100 % für alle VMAT-Patienten verglichen mit 80 und 73 % für die 3DCRT-Patienten. VMAT hat sich als eine praktikable Radiotherapietechnik bewiesen, die signifikant niedrigere Raten an akuter Organtoxizität und vielversprechende LRC- und DFS-Ergebnisse zeigt. Zukünftige Untersuchungen sollten darauf abzielen, die Vorteile von VMAT in Hinblick auf die Spättoxizität und das Langzeitüberleben zu analysieren.
- Open Access
- 2 March 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (3) , 4682-4697
The Anti-TNF-α Antibody Infliximab Inhibits the Expression of Fat-Transporter-Protein FAT/CD36 in a Selective Hepatic-Radiation Mouse Model
Previously, we reported a radiation-induced inflammation triggering fat-accumulation through fatty-acid-translocase/cluster of differentiation protein 36 (FAT/CD36) in rat liver. Furthermore, inhibition of radiation-induced FAT/CD36-expression by anti-tumor necrosis factor-α (anti-TNF-α) (infliximab) was shown in vitro. The current study investigates fat-accumulation in a mouse-model of single-dose liver-irradiation (25-Gray) and the effect of anti-TNF-α-therapy on FAT/CD36 gene-expression. Mice livers were selectively irradiated in vivo in presence or absence of infliximab. Serum- and hepatic-triglycerides, mRNA, and protein were analyzed by colorimetric assays, RT-PCR, Immunofluorescence and Western-Blot, respectively. Sudan-staining was used demonstrating fat-accumulation in tissue. In mice livers, early (1–3 h) induction of TNF-α-expression, a pro-inflammatory cytokine, was observed. It was followed by elevated hepatic-triglyceride level (6–12 h), compared to sham-irradiated controls. In contrast, serum-triglyceride level was decreased at these time points. Similar to triglyceride level in mice livers, Sudan staining of liver cryosections showed a quick (6–12 h) increase of fat-droplets after irradiation. Furthermore, expression of fat-transporter-protein FAT/CD36 was increased at protein level caused by radiation or TNF-α. TNF-α-blockage by anti-TNF-α showed an early inhibition of radiation-induced FAT/CD36 expression in mice livers. Immunohistochemistry showed basolateral and cytoplasmic expression of FAT/CD36 in hepatocytes. Moreover, co-localization of FAT/CD36 was detected with α-smooth muscle actin (α-SMA+) cells and F4/80+ macrophages. In summary, hepatic-radiation triggers fat-accumulation in mice livers, involving acute-phase-processes. Accordingly, anti-TNF-α-therapy prevented early radiation-induced expression of FAT/CD36 in vivo.
- 2 March 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (3) , 4682-4697
Open AccessThe Anti-TNF-α Antibody Infliximab Inhibits the Expression of Fat-Transporter-Protein FAT/CD36 in a Selective Hepatic-Radiation Mouse Model
Previously, we reported a radiation-induced inflammation triggering fat-accumulation through fatty-acid-translocase/cluster of differentiation protein 36 (FAT/CD36) in rat liver. Furthermore, inhibition of radiation-induced FAT/CD36-expression by anti-tumor necrosis factor-α (anti-TNF-α) (infliximab) was shown in vitro. The current study investigates fat-accumulation in a mouse-model of single-dose liver-irradiation (25-Gray) and the effect of anti-TNF-α-therapy on FAT/CD36 gene-expression. Mice livers were selectively irradiated in vivo in presence or absence of infliximab. Serum- and hepatic-triglycerides, mRNA, and protein were analyzed by colorimetric assays, RT-PCR, Immunofluorescence and Western-Blot, respectively. Sudan-staining was used demonstrating fat-accumulation in tissue. In mice livers, early (1–3 h) induction of TNF-α-expression, a pro-inflammatory cytokine, was observed. It was followed by elevated hepatic-triglyceride level (6–12 h), compared to sham-irradiated controls. In contrast, serum-triglyceride level was decreased at these time points. Similar to triglyceride level in mice livers, Sudan staining of liver cryosections showed a quick (6–12 h) increase of fat-droplets after irradiation. Furthermore, expression of fat-transporter-protein FAT/CD36 was increased at protein level caused by radiation or TNF-α. TNF-α-blockage by anti-TNF-α showed an early inhibition of radiation-induced FAT/CD36 expression in mice livers. Immunohistochemistry showed basolateral and cytoplasmic expression of FAT/CD36 in hepatocytes. Moreover, co-localization of FAT/CD36 was detected with α-smooth muscle actin (α-SMA+) cells and F4/80+ macrophages. In summary, hepatic-radiation triggers fat-accumulation in mice livers, involving acute-phase-processes. Accordingly, anti-TNF-α-therapy prevented early radiation-induced expression of FAT/CD36 in vivo.
- 9 January 2015
- Published by Springer Nature in Der Onkologe
- Vol. 21 (2) , 111-116
Moderne Bestrahlungstechniken
- 9 January 2015
- Published by Springer Nature in Der Onkologe
- Vol. 21 (2) , 111-116
Moderne Bestrahlungstechniken
- 1 January 2015
- Published by Springer Nature
- p. 79-91
Radiation Therapy in Patients with Non-curable Cancer
- 1 January 2015
- Published by Springer Nature
- p. 79-91
Radiation Therapy in Patients with Non-curable Cancer
- Open Access
STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
Chemoradiotherapy (CRT) represents a standard treatment for many human cancers, frequently combined with radical surgical resection. However, a considerable percentage of primary cancers are at least partially resistant to CRT, which represents a substantial clinical problem, because it exposes cancer patients to the potential side effects of both irradiation and chemotherapy. It is therefore exceedingly important to determine the molecular characteristics underlying CRT-resistance and to identify novel molecular targets that can be manipulated to re-sensitize resistant tumors to CRT. In this review, we highlight much of the recent evidence suggesting that the signal transducer and activator of transcription 3 (STAT3) plays a prominent role in mediating CRT-resistance, and we outline why inhibition of STAT3 holds great promise for future multimodal treatment concepts in oncology.
Open AccessSTAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
Chemoradiotherapy (CRT) represents a standard treatment for many human cancers, frequently combined with radical surgical resection. However, a considerable percentage of primary cancers are at least partially resistant to CRT, which represents a substantial clinical problem, because it exposes cancer patients to the potential side effects of both irradiation and chemotherapy. It is therefore exceedingly important to determine the molecular characteristics underlying CRT-resistance and to identify novel molecular targets that can be manipulated to re-sensitize resistant tumors to CRT. In this review, we highlight much of the recent evidence suggesting that the signal transducer and activator of transcription 3 (STAT3) plays a prominent role in mediating CRT-resistance, and we outline why inhibition of STAT3 holds great promise for future multimodal treatment concepts in oncology.
- 22 December 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 190 (2) , 199-203
Fractionated external beam radiotherapy of skull base metastases with cranial nerve involvement
Zusammenfassung Hintergrund und Ziele Schädelbasismetastasen treten häufig im Spätstadium vieler Tumorentitäten auf und können durch Schmerzen und neurologische Ausfälle die Lebensqualität der Patienten stark beeinträchtigen. In der vorliegenden Studie wurde retrospektiv eine fraktionierte externe Radiotherapie (EBRT) als palliative Behandlungsmöglichkeit bezüglich der Durchführbarkeit, der Akuttoxizität und des neurologischen Outcomes analysiert. Patienten und Methoden Es wurden 30 Patienten mit Schädelbasismetastasen und Hirnnervenausfällen mit einer mittleren Dosis von 31,6 Gy bestrahlt. Neurologische Symptome wurden vor, während und nach Radiotherapie erfasst. Sie wurden anhand der klinischen Syndrome nach der Lokalisation (mittlere Schädelgrube, Orbital-, Parasellär-, Foramen-jugulare- und Okzipitalkondylenregion) kategorisiert. Das neurologische Outcome wurde in Persistenz der Symptome, partielles Ansprechen, gutes Ansprechen und Komplettremission eingeteilt. Ergebnisse Vor Therapie wurden 37 klinische Syndrome diagnostiziert; hierbei wiesen 4 Patienten multiple Syndrome auf. Das Gesamtansprechen betrug 81,1 %, im Einzelnen 10,8 % in Komplettremission, 48,6 % mit gutem und 21,6 % mit partiellem Ansprechen. Zwei Patienten zeigten eine Grad-1-Toxizität der Haut und ein Patient eine Grad-1-Hämatotoxizität unter konkomitanter Chemotherapie. Das mediane Gesamtüberleben betrug 3,9 Monate bei einem medianen Follow-up von 45 Monaten. Schlussfolgerung Die fraktionierte externe Radiotherapie bei Schädelbasismetastasen mit Hirnnervenausfällen zeichnet sich durch gutes neurologisches Ansprechen, exzellente Durchführbarkeit und geringgradige Akuttoxizität aus. Diese Ergebnisse unterstreichen die Stellung von EBRT als Standardtherapie für diese Indikation.
- 22 December 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 190 (2) , 199-203
Fractionated external beam radiotherapy of skull base metastases with cranial nerve involvement
Zusammenfassung Hintergrund und Ziele Schädelbasismetastasen treten häufig im Spätstadium vieler Tumorentitäten auf und können durch Schmerzen und neurologische Ausfälle die Lebensqualität der Patienten stark beeinträchtigen. In der vorliegenden Studie wurde retrospektiv eine fraktionierte externe Radiotherapie (EBRT) als palliative Behandlungsmöglichkeit bezüglich der Durchführbarkeit, der Akuttoxizität und des neurologischen Outcomes analysiert. Patienten und Methoden Es wurden 30 Patienten mit Schädelbasismetastasen und Hirnnervenausfällen mit einer mittleren Dosis von 31,6 Gy bestrahlt. Neurologische Symptome wurden vor, während und nach Radiotherapie erfasst. Sie wurden anhand der klinischen Syndrome nach der Lokalisation (mittlere Schädelgrube, Orbital-, Parasellär-, Foramen-jugulare- und Okzipitalkondylenregion) kategorisiert. Das neurologische Outcome wurde in Persistenz der Symptome, partielles Ansprechen, gutes Ansprechen und Komplettremission eingeteilt. Ergebnisse Vor Therapie wurden 37 klinische Syndrome diagnostiziert; hierbei wiesen 4 Patienten multiple Syndrome auf. Das Gesamtansprechen betrug 81,1 %, im Einzelnen 10,8 % in Komplettremission, 48,6 % mit gutem und 21,6 % mit partiellem Ansprechen. Zwei Patienten zeigten eine Grad-1-Toxizität der Haut und ein Patient eine Grad-1-Hämatotoxizität unter konkomitanter Chemotherapie. Das mediane Gesamtüberleben betrug 3,9 Monate bei einem medianen Follow-up von 45 Monaten. Schlussfolgerung Die fraktionierte externe Radiotherapie bei Schädelbasismetastasen mit Hirnnervenausfällen zeichnet sich durch gutes neurologisches Ansprechen, exzellente Durchführbarkeit und geringgradige Akuttoxizität aus. Diese Ergebnisse unterstreichen die Stellung von EBRT als Standardtherapie für diese Indikation.
- 12 July 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 189 (10) , 874-880
Second primary malignancies in head and neck cancer patients
Patients treated for squamous cell carcinoma of the head and neck (HNSCC) carry a high risk of second primary malignancies (SPM). Recently, computed tomography (CT) of the chest was shown to significantly decrease the risk of death due to bronchial carcinoma (BC) in a cohort of smokers whose risk of BC is increased but might be lower than that of patients previously treated for HNSCC. Thus, the present study evaluated the potential benefit of CT and other examinations in the detection of SPM in HNSCC patients. Between July 2008 and November 2011, 118 participants underwent a prospective, systematic examination for SPM (13 women, 105 men, median age 62 years). All patients had been previously treated for HNSCC and showed no recurrence or distant metastases at the time of the study start. CT scans, ear–nose–throat endoscopy, and endoscopy of the esophagus and stomach were performed. Overall, 33 suspicious findings were clarified by additional investigations. In all, 26 SPM were confirmed in 21 of 118 patients (18 %; 10 lung, 7 HNSCC, 3 gastrointestinal, 1 renal). Eighteen of these 21 patients (86 %) underwent therapy with curative intent. The examinations revealed a high prevalence of curable stage SPM in HNSCC patients. Adapting a surveillance scheme including a chest CT is recommended. Patienten, welche bereits aufgrund eines Plattenepithelkarzinoms im Kopf-Hals-Bereich (HNSCC) behandelt wurden, weisen ein hohes Risiko für bösartige Zweittumore („second primary malignancies“, SPM) auf. In diesem Zusammenhang führte eine Computertomographie (CT) der Lunge in einer kürzlich veröffentlichten Studie bei Rauchern, welche bekanntlich ein erhöhtes Risiko für Bronchialkarzinome (BC) tragen, zu einer signifikanten Reduktion der Mortalität durch eben diese Tumore. Möglicherwiese ist das Risiko von HNSCC-Patienten, ein BC zu entwickeln, im Vergleich aber sogar höher. Aus diesem Grund evaluiert die vorliegende Studie einen möglichen Benefit einer CT und anderer Untersuchungen zur Feststellung eines Zweittumors bei HNSCC-Patienten. Zwischen Juli 2008 und November 2011 unterzogen sich 118 Studienteilnehmer prospektiv einer systematischen Untersuchung auf einen Zweittumor (13 Frauen, 105 Männer, medianes Alter 62 Jahre). Alle Patienten wurden zuvor aufgrund eines HNSCC behandelt und entwickelten bisher kein Lokalrezidiv oder Fernmetastasen. Bei allen Patienten wurden eine CT der Lunge, eine Panendoskopie des Hals-Nasen-Rachen-Bereichs und eine Endoskopie des Ösophagus und Magens durchgeführt. Insgesamt wurden 33 auffällige Befunde durch weitere Untersuchungen abgeklärt. Hierbei wurden bei 21 von 118 Patienten (18 %) 26 bösartige Tumore bestätigt (10 BC, 7 HNSCC, 3 ösophagogastrale Tumore und 1 Nierentumor). Insgesamt 18 dieser 21 Patienten (86 %) konnten erneut kurativ behandelt werden. Die vorliegenden Ergebnisse zeigen eine hohe Prävalenz an asymptomatischen, kurativ behandelbaren Zweittumoren bei HNSCC-Patienten. Eine Ergänzung der Routinenachsorge durch eine Thorax-Computertomographie wird empfohlen.
- 12 July 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 189 (10) , 874-880
Second primary malignancies in head and neck cancer patients
Patients treated for squamous cell carcinoma of the head and neck (HNSCC) carry a high risk of second primary malignancies (SPM). Recently, computed tomography (CT) of the chest was shown to significantly decrease the risk of death due to bronchial carcinoma (BC) in a cohort of smokers whose risk of BC is increased but might be lower than that of patients previously treated for HNSCC. Thus, the present study evaluated the potential benefit of CT and other examinations in the detection of SPM in HNSCC patients. Between July 2008 and November 2011, 118 participants underwent a prospective, systematic examination for SPM (13 women, 105 men, median age 62 years). All patients had been previously treated for HNSCC and showed no recurrence or distant metastases at the time of the study start. CT scans, ear–nose–throat endoscopy, and endoscopy of the esophagus and stomach were performed. Overall, 33 suspicious findings were clarified by additional investigations. In all, 26 SPM were confirmed in 21 of 118 patients (18 %; 10 lung, 7 HNSCC, 3 gastrointestinal, 1 renal). Eighteen of these 21 patients (86 %) underwent therapy with curative intent. The examinations revealed a high prevalence of curable stage SPM in HNSCC patients. Adapting a surveillance scheme including a chest CT is recommended. Patienten, welche bereits aufgrund eines Plattenepithelkarzinoms im Kopf-Hals-Bereich (HNSCC) behandelt wurden, weisen ein hohes Risiko für bösartige Zweittumore („second primary malignancies“, SPM) auf. In diesem Zusammenhang führte eine Computertomographie (CT) der Lunge in einer kürzlich veröffentlichten Studie bei Rauchern, welche bekanntlich ein erhöhtes Risiko für Bronchialkarzinome (BC) tragen, zu einer signifikanten Reduktion der Mortalität durch eben diese Tumore. Möglicherwiese ist das Risiko von HNSCC-Patienten, ein BC zu entwickeln, im Vergleich aber sogar höher. Aus diesem Grund evaluiert die vorliegende Studie einen möglichen Benefit einer CT und anderer Untersuchungen zur Feststellung eines Zweittumors bei HNSCC-Patienten. Zwischen Juli 2008 und November 2011 unterzogen sich 118 Studienteilnehmer prospektiv einer systematischen Untersuchung auf einen Zweittumor (13 Frauen, 105 Männer, medianes Alter 62 Jahre). Alle Patienten wurden zuvor aufgrund eines HNSCC behandelt und entwickelten bisher kein Lokalrezidiv oder Fernmetastasen. Bei allen Patienten wurden eine CT der Lunge, eine Panendoskopie des Hals-Nasen-Rachen-Bereichs und eine Endoskopie des Ösophagus und Magens durchgeführt. Insgesamt wurden 33 auffällige Befunde durch weitere Untersuchungen abgeklärt. Hierbei wurden bei 21 von 118 Patienten (18 %) 26 bösartige Tumore bestätigt (10 BC, 7 HNSCC, 3 ösophagogastrale Tumore und 1 Nierentumor). Insgesamt 18 dieser 21 Patienten (86 %) konnten erneut kurativ behandelt werden. Die vorliegenden Ergebnisse zeigen eine hohe Prävalenz an asymptomatischen, kurativ behandelbaren Zweittumoren bei HNSCC-Patienten. Eine Ergänzung der Routinenachsorge durch eine Thorax-Computertomographie wird empfohlen.